TU Darmstadt / ULB / TUprints

Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics

Bogen, Jan Patrick ; Grzeschik, Julius ; Jakobsen, Jørn ; Bähre, Alexandra ; Hock, Björn ; Kolmar, Harald (2021):
Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics. (Publisher's Version)
In: Frontiers in Oncology, 11, Frontiers, e-ISSN 2234-943X,
DOI: 10.26083/tuprints-00019435,
[Article]

[img]
Preview
Text
fonc-11-672262.pdf
Available under CC BY 4.0 International - Creative Commons, Attribution.

Download (3MB) | Preview
Item Type: Article
Origin: Secondary publication via sponsored Golden Open Access
Status: Publisher's Version
Title: Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics
Language: English
Abstract:

Bladder cancer is a frequent malignancy and has a clinical need for new therapeutic approaches. Antibody and protein technologies came a long way in recent years and new engineering approaches were applied to generate innovative therapeutic entities with novel mechanisms of action. Furthermore, mRNA-based pharmaceuticals recently reached the market and CAR-T cells and viral-based gene therapy remain a major focus of biomedical research. This review focuses on the engineering of biologics, particularly therapeutic antibodies and their application in preclinical development and clinical trials, as well as approved monoclonal antibodies for the treatment of bladder cancer. Besides, newly emerging entities in the realm of bladder cancer like mRNA, gene therapy or cell-based therapeutics are discussed and evaluated. As many discussed molecules exhibit unique mechanisms of action based on innovative protein engineering, they reflect the next generation of cancer drugs. This review will shed light on the engineering strategies applied to develop these next generation treatments and provides deeper insights into their preclinical profiles, clinical stages, and ongoing trials. Furthermore, the distribution and expression of the targeted antigens and the intended mechanisms of action are elucidated.

Journal or Publication Title: Frontiers in Oncology
Journal volume: 11
Publisher: Frontiers
Collation: 25 Seiten
Classification DDC: 500 Naturwissenschaften und Mathematik > 540 Chemie
600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin, Gesundheit
Divisions: 07 Department of Chemistry > Fachgebiet Biochemie
Date Deposited: 03 Sep 2021 12:31
Last Modified: 03 Sep 2021 12:31
DOI: 10.26083/tuprints-00019435
Corresponding Links:
URN: urn:nbn:de:tuda-tuprints-194359
Additional Information:

Keywords: antibody engineering, protein engineering, bladder cancer, urothelial carcinoma, ADC, immunotherapy, immuno-oncology, recombinant viral vector vaccines

URI: https://tuprints.ulb.tu-darmstadt.de/id/eprint/19435
Export:
Actions (login required)
View Item View Item